Explore the words cloud of the EBiSC2 project. It provides you a very rough idea of what is the project "EBiSC2" about.
The following table provides information about the project.
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
|Coordinator Country||Germany [DE]|
|Total cost||8˙872˙547 €|
|EC max contribution||4˙599˙648 € (52%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-03-01 to 2022-08-31|
Take a look of project's partnership.
|1||FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.||DE (MUNCHEN)||coordinator||2˙463˙250.00|
|2||CHARITE - UNIVERSITAETSMEDIZIN BERLIN||DE (BERLIN)||participant||999˙990.00|
|3||BIONEER A/S||DK (HOERSHOLM)||participant||374˙625.00|
|4||Department of Health||UK (Leeds)||participant||300˙208.00|
|5||KATHOLIEKE UNIVERSITEIT LEUVEN||BE (LEUVEN)||participant||236˙575.00|
|7||BAYER AKTIENGESELLSCHAFT||DE (Leverkusen)||participant||0.00|
|8||Eli Lilly and Company Limited||UK (Basingstoke)||participant||0.00|
|9||FUJIFILM CELLULAR DYNAMICS INC||US (MADISON WI)||participant||0.00|
|10||H. LUNDBECK AS||DK (VALBY)||participant||0.00|
|11||INSTITUT DE RECHERCHES SERVIER||FR (SURESNES)||participant||0.00|
|12||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
|13||NOVO NORDISK A/S||DK (BAGSVAERD)||participant||0.00|
|14||PFIZER LIMITED||UK (SANDWICH)||participant||0.00|
|15||TAKEDA DEVELOPMENT CENTRE EUROPE LTD||UK (LONDON)||participant||0.00|
|16||UCB BIOPHARMA SRL||BE (BRUXELLES)||participant||0.00|
EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique banking and distribution infrastructure for research use in response to the increasing demand for human induced pluripotent stem cells (iPSC). Significant progress towards this aim has been made by EBiSC1; further resources, however, are required to ensure self-sustainability. Key partners of EBiSC1 who have delivered major assets of the current bank, join efforts to establish EBiSC2 as self-sustainable, central bank. Based on a gap analysis of the EBiSC1 endeavours towards sustainability, and focussing on user demand, scientific excellence and productivity, EBiSC2 will deploy a business strategy for a sustainable, non-for-profit bank providing access to disease-relevant and quality-controlled iPSCs, along with comprehensive data and freedom to operate for academic and commercial use. To meet evolving requirements from industry and academia, the cell catalogue will be constantly enriched through on-demand generation of new iPSC lines, including gene-edited lines and isogenic controls, iPSC-derived and progenitor cells. EBiSC2 will distribute cell lines and develop a range of additional cell services (incl. screening panels of disease-relevant iPSC and control lines in ready-to-use-formats) to extend its offer, while reducing operational costs through state-of-the-art upscaling and automation enabling bulk production of standardised high-quality cells. Proof-of-concept studies performed jointly by academia and industry will demonstrate the reliability and robustness of the lines for disease modelling and screening and enrich the EBiSC2 catalogue with extensive data. To bundle resources, EBiSC2 focuses on collaboration with iPSC programmes and aims to serve as central hub for EU-funded projects to bank their iPSC lines, and thus, enable long-term access by the research community to the results of European investments.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBISC2" project.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EBISC2" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Bringing a prophylactic Ebola vaccine to licensureRead More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More